Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Inhibikase Therapeutics, Inc. - Common Stock (NQ:IKT)

1.840 -0.135 (-6.84%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Inhibikase Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Why Bed Bath & Beyond Jumped Around 25%; Here Are 68 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Why Hill International Is Trading Higher By 15%; Here Are 30 Stocks Moving Premarket
Gainers NewAge, Inc. (NASDAQ: NBEV) shares rose 19.7% to $0.2432 in pre-market trading. NewAge recently received Nasdaq notice on late filing of its form 10-Q. 
Via Benzinga
Recap: Inhibikase Therapeutics Q1 Earnings
Inhibikase Therapeutics (NASDAQ:IKT) reported its Q1 earnings results on Monday, May 16, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Scheduled For May 16, 2022
Companies Reporting Before The Bell • AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand. 
Via Benzinga
Why Chimerix Is Trading Higher By Over 19%, Here Are 53 Stocks Moving In Monday's Mid-Day Session
Gainers Advanced Human Imaging Limited (NASDAQ: AHI) shares jumped 53% to $1.04. Advanced Human Imaging announced Sunday it signed a Master Services Agreement with Estonia-based Activate Health OÜ. 
Via Benzinga
Recap Of Friday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Inhibikase Shares Shoot Higher As FDA Announced Clearance To Blood-Cell Cancer Study
The U.S. Food and Drug Administration (FDA) has reviewed Inhibikase Therapeutics’ (NASDAQ: IKT) Investigational New Drug (IND) application and issued a Study May Procced (SMP) letter for its drug... 
Via Benzinga
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc... 
Via Benzinga
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc... 
Via Benzinga
Exposures COVID-19
This Financial Services Stock Surged Around 116%; Here Are 86 Biggest Movers From Yesterday
Gainers Magic Empire Global Limited (NASDAQ: MEGL) shares jumped 115.7% to close at $17.73 on volatility following the company's IPO earlier this month. 
Via Benzinga
Why Viridian Therapeutics Is Trading Higher By Around 58%, Here Are 67 Stocks Moving In Monday's Mid-Day Session
Gainers Sunrise New Energy Co. Ltd. (NASDAQ: EPOW) shares jumped 118.2% to $4.4948. Sunrise New Energy said that the company changed its name from Global Internet of the People, Inc. to Sunrise New... 
Via Benzinga
Inhibikase Therapeutics: Q2 Earnings Insights
  Inhibikase Therapeutics (NASDAQ:IKT) reported its Q2 earnings results on Friday, August 12, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Scheduled For August 12, 2022
Companies Reporting Before The Bell • NeoGenomics (NASDAQ:NEO) is projected to report quarterly earnings at $0.44 per share on revenue of $218.26 million. 
Via Benzinga
Earnings Preview: Inhibikase Therapeutics
  Inhibikase Therapeutics (NASDAQ:IKT) is set to give its latest quarterly earnings report on Friday, 2022-08-12. Here's what investors need to know before the announcement. 
Via Benzinga
24 Stocks Moving in Wednesday's Pre-Market Session
Gainers Boxed, Inc. (NYSE: BOXD) rose 38.3% to $1.95 in pre-market trading. Boxed reported that Director Andrew Pearson bought 150,000 shares at an average price of $1.82 per share. 
Via Benzinga
Inhibikase Therapeutics's Return On Capital Employed Overview
Inhibikase Therapeutics (NASDAQ:IKT) brought in sales totaling $1.94 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 12.76%, resulting in a loss of $5.04... 
Via Benzinga
The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 Shortfall
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Earnings Outlook For Inhibikase Therapeutics
Inhibikase Therapeutics (NASDAQ:IKT) is set to give its latest quarterly earnings report on Thursday, 2022-03-31. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Earnings Scheduled For March 31, 2022
Companies Reporting Before The Bell • Trevena (NASDAQ:TRVN) is likely to report earnings for its fourth quarter. 
Via Benzinga
Inhibikase Targets A Substantial Market Following Presentation of Results Presented at The Barcelona Conference
The upcoming trial results are expected to show an excellent safety profile of the drug and perhaps some biomarkers that translate into efficacy. 
Via Talk Markets
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets. 
Via Benzinga
The Daily Biotech Pulse: Moderna Files For 2nd COVID Booster Shot Authorization, Lexicon Secures Debt Funding, Amneal Gets Sub-License to Manufacture Generic COVID Pill
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments... 
Via Benzinga
48 Biggest Movers From Yesterday
Gainers Splash Beverage Group, Inc. (NYSE: SBEV) shares jumped 70.6% to close at $1.80 on Tuesday after the company announced it received authorization to sell its TapouT... 
Via Benzinga
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc... 
Via Benzinga
Inhibikase Shares Interim 3-Month Toxicology Studies Data Of Parkinson's Candidate
Inhibikase Therapeutics Inc (NASDAQ: IKT) has announced interim three-month results from its ongoing chronic toxicology studies of oral IkT-148009 administered in... 
Via Benzinga
Inhibikase To Start Testing Its Parkinson's Candidate In Patients
The FDA has signed off Inhibikase Therapeutics Inc's (NASDAQ: IKT) Phase 1b extension study to evaluate its lead drug candidate IkT-148009 in Parkinson's... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12) Adagio Therapeutics, Inc. (... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.